Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jun;20(6):653-664.
doi: 10.1080/14712598.2020.1729735. Epub 2020 Feb 24.

Assessment and management of cytokine release syndrome and neurotoxicity following CD19 CAR-T cell therapy

Cassie K Chou  1   2 , Cameron J Turtle  1   3
Affiliations
Review

Assessment and management of cytokine release syndrome and neurotoxicity following CD19 CAR-T cell therapy

Cassie K Chou et al. Expert Opin Biol Ther. 2020 Jun.

Abstract

Introduction: The success of CD19 chimeric antigen receptor (CAR)-T cell therapy for treatment of CD19 positive malignancies has led to the FDA approval of two CD19 CAR-T cell products, tisagenlecleucel and axicabtagene ciloleucel, and ongoing clinical trials of new products. Cytokine release syndrome (CRS) and neurotoxicity are common toxicities associated with CD19 CAR-T cell therapies.Areas covered: This review will discuss CRS and neurotoxicity associated with CD19 CAR-T cell therapies, including clinical presentation, risk factors, pathophysiology, and therapeutic or prophylactic interventions.Expert opinion: In conjunction with improved understanding of the pathophysiology of CRS and neurotoxicity, we expect that the recent development of consensus guidelines for the evaluation of these toxicities will enhance management of patients undergoing CD19 CAR-T cell therapies.

Keywords: CAR-T cell; CD19 malignancies; chimeric antigen receptor; cytokine release syndrome; immunotherapy; leukemia; lymphoma; neurotoxicity.

PubMed Disclaimer

Conflict of interest statement

Declaration of Interests

CJ Turtle has received research funding from Juno/BMS, Nektar Therapeutics; is on scientific advisory boards for Precision Biosciences, T-CURX, Eureka Therapeutics, Caribou Biosciences, Myeloid Therapeutics, Arsenal Bio; has equity in Precision Biosciences, Eureka Therapeutics, Caribou Bioscience, Myeloid Therapeutics, Arsenal Bio; acted ad hoc on advisory boards (last 12 months) for , Kite/Gilead, , Allogene, PACT Pharma, Nektar Therapeutics, Astra Zeneca; and has patents pending to cover technology related to cellular therapies with Juno/BMS. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Figures

Figure 1:
Figure 1:
Brain MRI images from patients with severe neurotoxicity following CD19 CAR-T cell therapy. A, Symmetric edema of deep structures (arrowheads). B, Global cerebral edema with blurring of gray-white junction (stars) and slit-like ventricles (arrowhead). C, Diffuse leptomeningeal enhancement (arrowheads). D, focal white matter hyperintensities (arrowheads). (Modified and reprinted from [49])
See this image and copyright information in PMC

References

    1. Gardner RA, Finney O, Annesley C, et al. Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood. 2017. June 22;129(25):3322–3331. - PMC - PubMed

    1. Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N Engl J Med 2017. December 28;377(26):2531–2544.

      ••ZUMA-1 pivotal trial for axicabtagene ciloleucel in adults with relapsed/refractory NHL

    1. Locke FL, Neelapu SS, Bartlett NL, et al. Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma. Mol Ther 2017. January 4;25(1):285–295. - PMC - PubMed
    1. Locke FL, Ghobadi A, Jacobson CA, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial. The Lancet Oncology 2019;20(1):31–42. - PMC - PubMed
    1. Lee DW, Kochenderfer JN, Stetler-Stevenson M, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. The Lancet 2015;385(9967):517–528. - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources